Stock listing
NASDAQ:LIXT Lixte Biotechnology Holdings, Inc. Stock
Home listing (NASDAQ) of Lixte Biotechnology Holdings, Inc.
Follow Lixte Biotechnology Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LIXT
$2.56 USD +0.31 (+13.5%)
Close on Nov 20, 2026 · Data provided by Twelve Data
- Day range
- $2.13 – $2.58 USDNov 20, 2026
- Volume
- 257,009 sharesNov 20, 2026
- Market cap
- $29.78M USDAt the close on Nov 20, 2026 · price × 11.63M shares outstanding
- 52-week range
- $2.13 – $8.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $820,073 USDMedian day 194,876 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LIXT · Home | $2.56 USD | +0.305 (+13.5%) | 257,009 | $2.31 | $2.58 | $2.125 | $2.255 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LIXT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.56 | +0.305 | +13.5% | $2.31 | $2.58 | $2.125 | 257,009 | |
| $2.255 | -0.595 | -20.9% | $2.86 | $2.96 | $2.25 | 577,921 | |
| $2.85 | -0.15 | -5.0% | $2.96 | $2.99 | $2.545 | 347,117 | |
| $3.00 | +0.20 | +7.1% | $2.87 | $3.02 | $2.15 | 768,318 | |
| $2.80 | +0.45 | +19.1% | $2.36 | $2.986 | $2.16 | 446,209 | |
| $2.35 | -1.35 | -36.5% | $3.595 | $3.595 | $2.31 | 323,450 | |
| $3.70 | -0.05 | -1.3% | $3.61 | $3.71 | $3.28 | 243,927 | |
| $3.75 | -0.03 | -0.8% | $3.85 | $3.85 | $3.68 | 66,818 | |
| $3.78 | +0.21 | +5.9% | $3.57 | $3.85 | $3.43 | 256,697 | |
| $3.57 | -0.03 | -0.8% | $3.68 | $3.81 | $3.54 | 103,943 | |
| $3.60 | +0.11 | +3.2% | $3.47 | $3.67 | $3.275 | 244,112 | |
| $3.49 | -0.11 | -3.1% | $3.51 | $3.51 | $3.29 | 194,996 | |
| $3.60 | +0.08 | +2.3% | $3.54 | $3.68 | $3.45 | 104,466 | |
| $3.52 | +0.05 | +1.4% | $3.42 | $3.53 | $3.246 | 142,137 | |
| $3.47 | -0.09 | -2.5% | $3.51 | $3.552 | $3.12 | 281,158 | |
| $3.56 | +0.02 | +0.6% | $3.58 | $3.62 | $3.40 | 584,413 | |
| $3.54 | -0.49 | -12.2% | $3.99 | $3.99 | $3.53 | 240,403 | |
| $4.03 | +0.09 | +2.3% | $3.97 | $4.05 | $3.73 | 166,351 | |
| $3.94 | -0.10 | -2.5% | $3.98 | $4.01 | $3.595 | 217,390 | |
| $4.04 | +0.23 | +6.0% | $3.78 | $4.18 | $3.65 | 274,243 | |
| $3.81 | +0.21 | +5.8% | $3.55 | $3.85 | $3.50 | 173,386 | |
| $3.60 | +0.07 | +2.0% | $3.51 | $3.73 | $3.46 | 208,358 | |
| $3.53 | -0.19 | -5.1% | $3.65 | $3.78 | $3.52 | 226,820 | |
| $3.72 | -0.01 | -0.3% | $3.75 | $3.87 | $3.51 | 70,020 | |
| $3.73 | -0.15 | -3.9% | $3.93 | $3.97 | $3.35 | 317,252 | |
| $3.88 | -0.21 | -5.1% | $4.09 | $4.165 | $3.85 | 97,230 | |
| $4.09 | +0.14 | +3.5% | $3.96 | $4.12 | $3.61 | 296,064 | |
| $3.95 | -0.33 | -7.7% | $4.18 | $4.39 | $3.95 | 118,663 | |
| $4.28 | +0.11 | +2.6% | $4.11 | $4.39 | $4.11 | 403,066 | |
| $4.17 | -0.36 | -7.9% | $4.54 | $4.54 | $4.12 | 143,699 | |
| $4.53 | +0.26 | +6.1% | $4.32 | $4.65 | $4.275 | 165,491 | |
| $4.27 | +0.02 | +0.5% | $4.22 | $4.43 | $4.22 | 71,844 | |
| $4.25 | -0.095 | -2.2% | $4.24 | $4.45 | $4.221 | 126,196 | |
| $4.345 | +0.33 | +8.2% | $3.98 | $4.40 | $3.98 | 146,665 | |
| $4.015 | -0.105 | -2.5% | $4.12 | $4.122 | $3.852 | 177,771 | |
| $4.12 | +0.26 | +6.7% | $3.85 | $4.19 | $3.84 | 140,098 | |
| $3.86 | -0.065 | -1.7% | $3.90 | $4.10 | $3.82 | 153,771 | |
| $3.925 | +0.175 | +4.7% | $3.71 | $3.96 | $3.60 | 234,603 | |
| $3.75 | +0.15 | +4.2% | $3.60 | $3.83 | $3.44 | 228,403 | |
| $3.60 | +0.02 | +0.6% | $3.57 | $3.73 | $3.52 | 106,987 | |
| $3.58 | -0.05 | -1.4% | $3.61 | $3.855 | $3.56 | 194,756 | |
| $3.63 | +0.105 | +3.0% | $3.63 | $3.64 | $3.51 | 62,672 | |
| $3.525 | -0.295 | -7.7% | $3.78 | $3.79 | $3.39 | 278,465 | |
| $3.82 | +0.14 | +3.8% | $3.73 | $4.01 | $3.73 | 341,710 | |
| $3.68 | +0.07 | +1.9% | $3.64 | $3.74 | $3.56 | 137,635 | |
| $3.61 | 0.00 | 0.0% | $3.64 | $3.74 | $3.56 | 295,210 | |
| $3.61 | +0.12 | +3.4% | $3.50 | $3.69 | $3.50 | 150,539 | |
| $3.49 | +0.13 | +3.9% | $3.32 | $3.63 | $3.25 | 185,578 | |
| $3.36 | +0.09 | +2.8% | $3.21 | $3.44 | $3.16 | 164,021 | |
| $3.27 | -0.27 | -7.6% | $3.50 | $3.71 | $3.26 | 200,510 | |
| $3.54 | -0.17 | -4.6% | $3.69 | $3.72 | $3.50 | 276,640 | |
| $3.71 | 0.00 | 0.0% | $3.68 | $3.87 | $3.60 | 143,167 | |
| $3.71 | -0.145 | -3.8% | $3.86 | $3.99 | $3.71 | 188,844 | |
| $3.855 | -0.175 | -4.3% | $4.03 | $4.03 | $3.75 | 238,587 | |
| $4.03 | +0.375 | +10.3% | $3.69 | $4.05 | $3.51 | 322,404 | |
| $3.655 | -0.055 | -1.5% | $3.72 | $3.92 | $3.555 | 326,729 | |
| $3.71 | -0.39 | -9.5% | $4.06 | $4.19 | $3.67 | 387,151 | |
| $4.10 | -0.04 | -1.0% | $4.17 | $4.37 | $4.00 | 355,407 | |
| $4.14 | -0.17 | -3.9% | $4.34 | $4.40 | $4.065 | 137,990 | |
| $4.31 | -0.11 | -2.5% | $4.30 | $4.45 | $4.22 | 125,870 | |
| $4.42 | +0.24 | +5.7% | $4.23 | $4.45 | $4.08 | 181,195 | |
| $4.18 | -0.02 | -0.5% | $4.16 | $4.31 | $4.03 | 102,696 | |
| $4.20 | +0.05 | +1.2% | $4.20 | $4.49 | $4.10 | 288,900 | |
| $4.15 | -0.15 | -3.5% | $4.31 | $4.55 | $4.15 | 130,900 | |
| $4.30 | +0.09 | +2.1% | $4.30 | $4.44 | $4.24 | 166,100 | |
| $4.21 | -0.10 | -2.3% | $4.26 | $4.44 | $4.09 | 133,000 |
- Ticker
- NASDAQ:LIXT
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Jul 6, 2026
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
Latest deck · July 2026
Nomad Power Systems — Investor Presentation (July 2026)
Investor deck · 58 slides
Latest news
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
Jul 6, 2026
Closed $7.34 (+1.8%) on Jul 6, 2026
LIXTE Joins Russell Microcap Index
Jun 26, 2026
Closed $7.19 (+8.1%) on Jun 26, 2026
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
Jun 18, 2026
Closed $7.61 (+9.3%) on Jun 18, 2026
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
Jun 12, 2026
Closed $6.19 (-14.6%) on Jun 12, 2026
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
Jun 3, 2026
Closed $6.71 (-4.7%) on Jun 3, 2026
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
Jun 1, 2026
Closed $7.21 (+15.4%) on Jun 1, 2026
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
May 14, 2026
Closed $5.16 (+2.4%) on May 15, 2026
LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape
Apr 20, 2026
Closed $3.44 (-4.7%) on Apr 20, 2026
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
Apr 13, 2026
Closed $2.93 (-3.9%) on Apr 13, 2026
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships
Apr 10, 2026
Closed $3.05 (+5.2%) on Apr 10, 2026
Lixte Biotechnology Holdings, Inc. on 6ix
- News releases
- 34 in the last 12 months · 97 in all · newest Jul 6, 2026 · oldest 2020
- Decks
- 2 decks · latest July 2026
Where Lixte Biotechnology Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LIXT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LIXT | BOATS | United States | USD |
| gettex:8640 | gettex | Germany | EUR |
| Munich:8640 | Munich | Germany | EUR |
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.43
Team and board
Officers
| Officer | Role |
|---|---|
| Geordan Pursglove | Chairman of the Board of Directors, President and Chief Executive Officer |
| Braxten Gorrill | Chief Financial Officer |
| Chris McKay | Chief Operating Officer |
| Huda Almashhadany | Chief of Product & VP of Operations |
| Jim Allan | Director of Sales |
Board
| Director | Role |
|---|---|
| Geordan Pursglove | Chairman of the Board of Directors, President and Chief Executive Officer |
| Guy Primus | Director |
| Jason Sawyer | Director |
| John Travaglini | Director |
| Lourdes Felix | Director |
| Michael Holloway | Director |
| Stuart Porter | Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Nomad Power Systems — Investor Presentation (July 2026) | Investor deck | 58 slides | July 2026 |
| Investor Presentation (December 2022) | Investor deck | 20 slides | Dec 6, 2022 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common Units (or Pre-Funded Units) of common stock and common warrants Announced: about US$4.3M · US$4.09 a unit · Warrants at US$3.96 for 60 months · Spartan Capital Securities, LLC Dealers: Spartan Capital Securities, LLC (lead) Use of proceeds: General corporate purposes and working capital | Dec 18, 2025 |
| Registered direct offering of shares of Common Stock (or Pre-Funded Warrants) Closed: US$1.5M raised · US$1.54 a share · Spartan Capital Securities, LLC Dealers: Spartan Capital Securities, LLC (lead) Use of proceeds: General corporate purposes and working capital | Jul 8, 2025 |
| Private placement of common stock (or pre-funded warrants), Series B convertible preferred stock and common warrants Closed: US$5M raised · Warrants at US$1 for 60 months · Spartan Capital Securities, LLC Dealers: Spartan Capital Securities, LLC (lead) Use of proceeds: General corporate purposes and working capital | Jul 2, 2025 |
| Registered direct offering of registered direct offering Closed: US$1.05M raised · US$2.415 a share · Warrants at US$2.29 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Mar 27, 2025 |
| Public offering of securities under Form S-1 registration statement Cancelled: public offering | Feb 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Cap table
Built by 6ix from Lixte Biotechnology Holdings, Inc.’s releases · as of Dec 18, 2025
- Common shares
- 11,632,944
- Fully diluted
- 11,632,944
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 11,632,944 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.00 · expire about Jul 2030 |
| Warrants · US$2.29 · expire about Feb 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,632,944 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Geordan Pursglove Other companies: Powell Max Limited (CEO and Chairman, Director · Since at least Mar 18, 2026); GridAI Technologies Corp. (Director · Since at least Aug 11, 2025) | Chairman of the Board of Directors, President and Chief Executive Officer · Since at least Jun 16, 2025 |
| Jason Sawyer Other companies: Greenland Mines Ltd (Director · Since at least Jul 22, 2026); GridAI Technologies Corp. (Chief Executive Officer, Director · Since at least Mar 31, 2026) | Director · Since at least Mar 31, 2026 |
| Stuart D. Porter Other companies: GameSquare Holdings, Inc. (Director · Since at least Jul 10, 2026); AirJoule Technologies Corporation (Director · Since at least May 28, 2026) | Director · Since at least May 29, 2026 |
| Bastiaan Jeroen van der Baan | President and CEO, Director · Jun 17, 2022 – Oct 3, 2023 · Past |
| Braxten Gorrill | Chief Financial Officer · Since at least Nov 4, 2026 |
| Chris McKay | Chief Operating Officer · Since at least Nov 4, 2026 |
| Gil Schwartzberg | Director · Apr 9, 2021 – Dec 31, 2021 · Past |
| Guy Primus | Director · Since at least Sep 1, 2025 |
| Huda Almashhadany | Chief of Product & VP of Operations · Since at least Nov 4, 2026 |
| James Miser | Chief Medical Officer · Nov 6, 2022 – Nov 21, 2022 · Past |
All 18 people
| Person | Seat |
|---|---|
| Jim Allan | Director of Sales · Since at least Nov 4, 2026 |
| John Travaglini | Director · Since at least Jun 18, 2026 |
| Lourdes Felix | Director · Since at least Mar 31, 2026 |
| Michael Holloway | Director · Since at least Jul 18, 2025 |
| Philip F Palmedo | Director · Nov 30, 2020 – Jun 30, 2022 · Past |
| Rene Bernards | Director · Since at least Jun 15, 2022 |
| Sidney Braun | CEO of Liora Technologies Europe Subsidiary · Feb 18, 2026 – Nov 5, 2026 · Past |
| Sze Chun Winson Ho | Director · Jan 6, 2021 – Jan 6, 2021 · Past |
Log in to ask 6ix AI your own questions about Lixte Biotechnology Holdings, Inc.